Breaking News

Almac, TTP Form FLT Pact

January 7, 2013

Aims to provide enhanced screening performance

Almac and TTP Labtech have formed an alliance in the field of fluorescence lifetime (FLT) technology to provide enhanced screening performance. The alliance aims to provide customers with access to a broad range of biological applications coupled with the next generation of microplate reader technology.
According to the companies, FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform that enables the user to avoid interference from fluorescent compounds within a screening library. Almac’s FLEXYTE assays now have FLT technology to provide a more efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many therapeutic target classes including: kinases, proteases, phosphatases, DUB, and epigenetic targets.
TTP Labtech’s Ameon system is a next-generation FLT reader technology, offering real-time decay curve analysis, faster and more precise data quality, and can be integrated into HTS workflows, according to the company.
“The development of the Ameon reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s FLEXYTE customers will be able to benefit from this advance in reader technology,” said Dr. Stephen Barr, president and managing director of Almac Sciences.
“We are excited by the potential of the FLEXYTE and Ameon reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds,” said Dr. Wayne Bowen, chief scientific officer of TTP Labtech.
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug